Newsroom

Press Releases

EQRx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Wednesday, March 23, 2022

3.9.2022
Download

EQRx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Wednesday, March 23, 2022

 EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference call and webcast on Wednesday, March 23, 2022, at 8:00 a.m. ET to report its fourth quarter and full year 2021 financial results and provide a business update.

A live webcast can be accessed by visiting the Investors section of the Company’s website at investors.eqrx.com. The conference call can be accessed by dialing 855-718-8094 (domestic) or 484-747-6788 (international) and referring to conference ID 4596972. The webcast will be made available for replay on the Company’s website beginning approximately two hours after the event.

About EQRx
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and providers. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRxIncLinkedIn, Instagram: @eqrxinc.

EQRx™ and Remaking Medicine™ are trademarks of EQRx.

EQRx Contacts:

Media:
Dan Budwick
1AB
dan@1abmedia.com

Investors:
investors@eqrx.com

Go to EQRx global home page

This site is intended for a global audience but it may not be suitable for some countries.
Choose the US Site for info specific to the United States.

© 2023 EQRx, Inc. and its subsidiaries. EQRx and Remaking Medicine are trademarks of EQRx.

Trademarks on this website are protected by registration and common law rights in many countries throughout the world.

MED-00110 | February 2023